New product launches will inject competition into the SLE market.
By Jacoba Procter, Content Manager
9 April 2016
I joined Datamonitor Healthcare as an analyst at the end of 2009 and I worked for a number of years covering immunology ...
Read full bio
Datamonitor Healthcare forecasts high growth in the systemic lupus erythematosus (SLE) market over the next 10 years, as new product launches replace historical off-label treatment, and increase the overall use of targeted therapies. After over 50 years without a new product approval for SLE, Benlysta achieved both US and EU approvals in 2011, opening the door for a new era in SLE treatment. Despite strong initial hype, Benlysta’s uptake has been low, in large part due to mixed efficacy results, such that new products launching in this space will face minimal competition. While each subsequent launch is forecast to reduce Benlysta’s patient share, new products will primarily derive revenue from tapping into new patients not yet treated with targeted therapy, with rheumatologists eager to adopt new treatment options. This increased uptake of high-priced therapies will drive the growth seen in this market over the next 10 years.
Timeline: approval/launch dates of key systemic lupus erythematosus therapies
Source: Datamonitor Healthcare
This ResearchWire is based on Datamonitor Healthcare’s Systemic Lupus Erythematosus content – covering a detailed look at the challenges remaining in the pipeline, as well as a forecast of new product launches.
Get your free demo today – simply fill out the form to the right.